IXcore

iXcore Group stands as a prominent French venture capital organization established in 2001, dedicating its investment strategy to the biotech and deeptech sectors. With over two decades of experience navigating the complex landscape of scientific innovation, iXcore has built a reputation for identifying promising technologies with transformative potential. The firm leverages its deep industry knowledge and extensive network to provide more than just capital to its portfolio companies, offering strategic guidance and operational support throughout their growth journey. iXcore's investment philosophy centers on backing visionary entrepreneurs developing breakthrough solutions to significant global challenges.

The firm's biotech investments span a diverse range of therapeutic areas, including oncology, neurodegenerative diseases, and rare genetic disorders. iXcore demonstrates particular interest in novel drug discovery platforms, precision medicine approaches, and advanced therapeutic modalities such as cell and gene therapies. On the deeptech front, the group focuses on companies developing cutting-edge technologies with applications across industries, including artificial intelligence, quantum computing, advanced materials, and sustainable energy solutions. This dual focus allows iXcore to identify unique cross-sector opportunities and facilitate valuable collaborations between portfolio companies.

iXcore typically engages with companies at early to mid-stages of development, from seed funding through Series B rounds, though it maintains flexibility to support promising ventures throughout their lifecycle. The firm's investment strategy emphasizes thorough scientific due diligence, evaluating not only technological innovation but also market potential, regulatory pathways, and scalability. With headquarters in France, iXcore maintains a pan-European investment scope while selectively pursuing opportunities in North America and emerging biotech hubs globally. This geographic diversity enriches the firm's perspective and creates valuable cross-border opportunities for portfolio companies.

Beyond financial backing, iXcore distinguishes itself through active involvement in portfolio company development. The firm's team comprises seasoned investment professionals with backgrounds spanning scientific research, pharmaceutical development, technology commercialization, and entrepreneurship. This multidisciplinary expertise enables iXcore to provide meaningful strategic guidance on critical decisions from clinical development strategies to market entry approaches. The group has established a notable track record of successful exits through both acquisitions by industry leaders and public market listings, cementing its position as a valuable partner for ambitious founders seeking to transform scientific breakthroughs into commercial successes.